Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis

Posted April 9, 2025

Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.

Health News is provided as a service to Adams Pharmacy site users by HealthDay. Adams Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.

Get Healthy!

Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis

Health News is provided as a service to Adams Pharmacy site users by HealthDay. Adams Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.

Copyright © 2025 HealthDay All Rights Reserved.

Tags

Site Navigation

Contact Us

Patient Resources

Get Healthy!

Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis

Health News is provided as a service to Adams Pharmacy site users by HealthDay. Adams Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.

Copyright © 2025 HealthDay All Rights Reserved.

Share

Tags

Site Navigation

Contact Us